Contributed Commentary by Kyle Given, CluePoints

October 6, 2026 | Risk-based quality management (RBQM) is increasingly taking center stage in clinical research. Since it was first mandated in ICH E6(R2) the model has laid the foundation for risk-based approaches across the industry. With ICH E6(R3) marking a decisive shift from checklist-based compliance to proportionate, risk-driven quality management the model has more to offer than ever. 

Today, RBQM offers not just regulatory compliance but the ability to add measurable value to drug development and sponsor organizations. However, many organizations are still operating with fragmented tools, static risk registers and reactive monitoring models. To unlock the true power of RBQM, the industry needs to embrace its potential as a live, operational oversight model. 

A Shifting Regulatory Landscape 

ICH E6(R3) marked a crucial turning point in clinical trial management. Instead of the rigid application of guidelines, it encouraged the industry to leverage proportional risk, digital technologies, and site and participant-centric practices. Crucially, clinical trial stakeholders are now expected to identify and focus on elements that are Critical to Quality (CtQ), including participant safety, from the start of trial planning. The latest guideline emphasizes Quality-by-Design (QbD) and processes that are built ‘right-first-time’ rather than traditional reactive approaches.  

At the same time, regulators are increasingly backing the use of real-world data (RWD) and real-world evidence (RWE). Risk-based approaches have been shown to be essential to obtain robust RWE. With the potential for real-time clinical trials (RTCTs) also on the horizon, it is more important than ever that RBQM models connect study-level risk detection and central analytics to detect issues earlier and focus monitoring where it matters most. Once that has been achieved, RBQM can achieve not just regulatory confidence but data integrity and operational efficiency. 

Benefits Beyond Regulatory Compliance 

Despite regulatory backing, industry-wide adoption of RBQM has historically been held back by a lack of quantitative evidence on its ROI. However, new evidence clearly demonstrates ROI at both the clinical trial and development-program level. RBQM use is associated with reductions of 8%-19% in clinical phase durations and traditional monitoring cost reductions of up to 18%. Total clinical trial ROIs range from $3.2 million in Phase I to $18.9 million in Phase III.  Program-level expected Net Present Value (eNPV) gains range from $3.8 million in Phase I to $13.8 million in Phase III. This makes a clear business case for RBQM-enabled trials. 

Crucially, these benefits are unlocked without compromising patient safety or data integrity. This is because, unlike exhaustive methods like 100% Source Data Verification (SDV), RBQM enables centralized, risk-based oversight of trial data. Tools such as Key Risk Indicators (KRIs), Quality Tolerance Limits (QTLs) and statistical monitoring all help to ensure teams can focus their efforts where CtQ issues are most likely to occur.  

There are also other, more overlooked, advantages to embracing an operational model of RBQM. Fewer site visits mean reduced contributions to greenhouse gas emissions. RBQM can also be used to support proactive site inspection readiness, including roles like Quality Assurance (QA). Risk-based methodologies offer a level of strategic oversight that increases the chances of approval, especially when the same approaches are used by global health authorities to interrogate clinical data and select sites for inspection.  

As RBQM technologies evolve they are also being used for more unconventional applications such as streamlining and strengthening the acquisition process. For example, when companies and assets are acquired, algorithms can surface data trends and discrepancies, giving sponsors a clearer idea of what risks they are inheriting. This expands RBQM beyond traditional trial oversight and into broader strategic operations. 

The Elements Needed for Effective Change 

There are three crucial elements needed to adopt RBQM as a live operational model and unlock the full potential of the benefits outlined above. The first is the use of Central Monitoring (CM) to effectively identify risk at a study and program level. The second is to use adaptive site monitoring to act on the insights generated precisely, efficiently, and in real time. The third is expert consulting which ensures the framework, governance, SOPs, and change management are in place so RBQM is fully embedded at an organizational level. This unified approach allows sponsors to capture all evidence in a single, audit-ready environment, providing a clear inspection narrative. 

However, much like the shift from paper to digital, RBQM also requires operational and cultural changes. Cross-functional critical thinking and accountability should be encouraged, with proactive risk management and open communication. There also needs to be education on the benefits of RBQM beyond cost savings, with an emphasis on quality and CtQ issues. To ease the transition to an operational RBQM model, organizations should: 

RBQM has evolved from a regulatory checklist into a live operating model connecting study-level risk detection and central analytics with site-level prioritization and action to detect issues earlier, focus monitoring where it matters most, and demonstrate GCP-aligned oversight with confidence. 

This evolution offers the opportunity to unlock previously unforeseen benefits. However, to truly seize the opportunities on offer, drug development and sponsor organizations need to focus not just on compliance but on embedding proportionality, critical thinking and collaborative risk-based approaches from the start of trial design. 

Kyle Given, RBQM Market Owner & Strategy Lead at CluePoints, is an industry leader in Risk-Based Quality Management (RBQM), with more than a decade of experience helping sponsors and CROs transform clinical trial operations through data-driven quality oversight. Throughout his career, Kyle has led the design, implementation, and commercialization of RBQM strategies across global pharmaceutical organizations. He has advanced RBQM through executive leadership roles at Johnson & Johnson, Syneos Health, Innovaderm, and now CluePoints, where he focuses on market strategy, product adoption, and enabling organizations to realize the full value of modern RBQM solutions. He can be reached at Kyle.Given@Cluepoints.com.